Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
The Lancet. Oncology
|
December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology
|
February 5, 2026
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits
Henry C Y Wong, J Isabelle Choi, Gustavo Nader Marta, et al.
European Urology Oncology
|
September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
The Lancet. Oncology
|
November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Anna Wilkins, Helen Mossop, Isabel Syndikus, et al.
Clinical Genitourinary Cancer
|
June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
Diletta Bianchini, David Lorente, Pasquale Rescigno, et al.
European Urology
|
December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
The Lancet. Oncology
|
March 13, 2022
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial
David Dearnaley, Victoria Hinder, Adham Hijab, et al.
Nature Cancer
|
July 12, 2024
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
Javier Fernandez-Mateos, George D Cresswell, Nicholas Trahearn, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
The Lancet. Oncology
|
December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology
|
February 5, 2026
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits
Henry C Y Wong, J Isabelle Choi, Gustavo Nader Marta, et al.
European Urology Oncology
|
September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
The Lancet. Oncology
|
November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Anna Wilkins, Helen Mossop, Isabel Syndikus, et al.
Clinical Genitourinary Cancer
|
June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
Diletta Bianchini, David Lorente, Pasquale Rescigno, et al.
European Urology
|
December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
The Lancet. Oncology
|
March 13, 2022
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial
David Dearnaley, Victoria Hinder, Adham Hijab, et al.
Nature Cancer
|
July 12, 2024
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
Javier Fernandez-Mateos, George D Cresswell, Nicholas Trahearn, et al.
Page
of 9